background
substanti
disagr
level
asymptomat
sever
acut
respiratori
syndrom
coronaviru
infect
popul
disagr
result
part
interpret
studi
report
proport
asymptomat
peopl
detect
singl
point
review
question
amongst
peopl
becom
infect
proport
experi
symptom
infect
amongst
peopl
infect
asymptomat
diagnos
proport
develop
symptom
later
proport
transmiss
account
peopl
either
asymptomat
throughout
infect
presymptomat
method
rapid
live
systemat
review
protocol
http
search
pubm
embas
biorxiv
medrxiv
use
live
evid
databas
literatur
includ
studi
peopl
diagnos
revers
transcriptas
pcr
rtpcr
document
followup
symptom
statu
begin
end
followup
model
studi
studi
select
data
extract
bia
assess
done
one
review
verifi
second
disagr
resolv
discuss
third
review
use
commoneffect
model
synthesis
proport
compar
studi
result
screen
studi
includ
estim
upper
bound
proport
asymptomat
infect
confid
interv
eight
studi
select
bia
like
public
bia
affect
famili
case
investig
studi
one
statist
model
studi
estim
true
proport
asymptomat
infect
credibl
interv
estim
proport
presymptomat
individu
four
studi
heterogen
combin
model
studi
infect
result
transmiss
presymptomat
individu
smaller
contribut
substanti
disagr
level
asymptomat
sever
acut
respiratori
syndrom
coronaviru
infect
popul
differ
extrem
author
world
health
organ
report
state
proport
truli
asymptomat
infect
unclear
appear
rel
rare
appear
major
driver
transmiss
contrast
report
new
infect
found
singl
day
led
statement
larg
major
coronaviru
infect
result
symptom
disagr
result
part
interpret
studi
report
proport
asymptomat
peopl
detect
singl
point
studi
includ
peopl
remain
asymptomat
throughout
known
presymptomat
develop
symptom
coronaviru
diseas
covid
follow
least
end
incub
period
day
full
spectrum
distribut
complet
asymptomat
mild
nonspecif
symptom
viral
pneumonia
respiratori
distress
syndrom
death
yet
known
without
follow
howev
proport
asymptomat
presymptomat
infect
determin
accur
estim
proport
true
asymptomat
presymptomat
infect
need
urgent
contribut
overal
transmiss
popul
level
determin
appropri
balanc
control
measur
predomin
rout
transmiss
peopl
symptom
strategi
focu
test
follow
isol
infect
individu
quarantin
contact
howev
transmiss
peopl
without
symptom
social
distanc
measur
reduc
contact
peopl
might
infecti
prioritis
object
studi
address
three
question
amongst
peopl
becom
infect
proport
experi
symptom
infect
amongst
peopl
infect
asymptomat
diagnos
proport
develop
symptom
later
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
proport
transmiss
account
peopl
either
asymptomat
throughout
infect
presymptomat
conduct
rapid
systemat
review
provid
relev
evid
public
health
emerg
intern
concern
protocol
review
publish
open
scienc
framework
http
report
find
accord
prefer
report
item
systemat
review
metaanalys
conduct
search
march
search
live
evid
databas
univers
bern
institut
social
prevent
medicin
ispm
http
includ
daili
updat
search
four
electron
databas
medlinepubm
embas
biorxiv
medrxiv
articl
medic
subject
head
keyword
infect
review
result
contain
asymp
titl
abstract
http
also
examin
articl
suggest
expert
refer
list
retriev
mathemat
model
studi
systemat
review
includ
studi
peopl
diagnos
revers
transcriptas
pcr
rtpcr
document
followup
symptom
statu
begin
end
followup
includ
contact
trace
investig
case
seri
cohort
studi
case
control
studi
statist
mathemat
model
studi
appli
languag
restrict
search
exclud
follow
studi
type
case
report
singl
patient
surveil
data
case
seri
patient
enrol
consecut
report
primari
data
found
anoth
includ
public
mathemat
model
studi
specif
estim
quantiti
specifi
review
question
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
one
review
select
studi
base
predefin
inclus
exclus
criteria
second
review
verifi
includ
exclud
studi
report
identif
exclus
inclus
studi
flowchart
figur
one
review
extract
data
use
prepilot
extract
form
electron
data
captur
system
redcap
vanderbilt
univers
usa
second
review
verifi
extract
data
use
queri
system
redcap
case
disagr
third
review
consult
disagr
resolv
discuss
contact
studi
author
clarif
extract
variabl
includ
limit
studi
design
countri
andor
region
studi
set
popul
age
review
outcom
length
followup
primari
outcom
review
question
proport
asymptomat
infect
experi
symptom
followup
proport
infect
symptom
time
test
develop
symptom
followup
estim
proport
includ
uncertainti
interv
transmiss
account
peopl
asymptomat
presymptomat
two
author
independ
assess
risk
bia
third
review
resolv
disagr
consensu
achiev
review
question
adapt
joanna
brigg
institut
critic
apprais
checklist
case
seri
adapt
tool
includ
item
inclus
criteria
measur
asymptomat
statu
followup
cours
diseas
avail
numer
denomin
ad
item
repres
sourc
target
popul
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
tool
assess
risk
bia
preval
studi
review
question
use
tool
assess
credibl
mathemat
model
studi
use
metaprop
function
meta
packag
version
r
version
display
studi
find
question
forest
plot
confid
interv
ci
estim
use
clopperpearson
method
synthesis
proport
compar
studi
term
design
popul
use
random
commoneffect
model
betweenstudi
varianc
close
zero
present
result
commoneffect
analysi
screen
studi
figur
includ
six
studi
report
famili
contact
trace
investig
china
two
studi
popul
evacu
wuhan
diamond
princess
cruis
ship
one
statist
model
studi
base
passeng
diamond
princess
two
mathemat
model
studi
proport
asymptomat
infect
six
famili
contact
investig
includ
peopl
one
individu
remain
asymptomat
throughout
followup
tabl
one
studi
contribut
three
cluster
studi
includ
adolesc
young
adult
admit
hospit
chonq
author
report
nine
case
investig
total
four
symptomat
two
includ
person
asymptomat
admiss
develop
symptom
later
nine
asymptomat
case
identifi
total
followup
last
possibl
day
exposur
rang
day
tabl
exce
accept
incub
period
day
age
report
six
asymptomat
case
two
children
age
month
year
three
asymptomat
case
transmiss
individu
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
report
commoneffect
summari
proport
asymptomat
contact
investig
ci
figur
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
two
studi
report
studi
popul
evacu
set
transmiss
confirm
tabl
figur
nishiura
et
al
report
japanes
nation
evacu
wuhan
test
posit
rtpcr
four
asymptomat
author
report
day
follow
four
remain
asymptomat
tabata
et
al
report
sampl
passeng
evacu
diamond
princess
cruis
ship
test
posit
rtpcr
follow
hospit
japan
peopl
hospit
follow
median
day
interquartil
rang
day
thirtythre
remain
asymptomat
end
followup
period
februari
commoneffect
summari
proport
infect
individu
remain
asymptomat
ci
estim
two
studi
type
statist
compat
commoneffect
summari
studi
ci
figur
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
report
asymptomat
test
author
estim
time
infect
use
publish
data
adjust
proport
peopl
would
develop
symptom
right
censor
bayesian
framework
estim
follow
end
incub
period
true
proport
asymptomat
infect
would
credibl
interv
cr
includ
four
studi
tabl
figur
three
studi
china
peopl
detect
rtpcr
follow
hospit
three
studi
author
report
asymptomat
case
detect
contact
investig
patient
present
symptom
two
studi
patient
develop
symptom
includ
patient
shenzhen
studi
patient
follow
clearanc
measur
repeat
neg
rtpcr
test
result
third
hospitalbas
studi
nanj
five
asymptomat
case
develop
symptom
within
one
three
day
admiss
anoth
thirteen
show
viral
clearanc
two
neg
rtpcr
test
result
remaind
still
posit
rtpcr
test
result
develop
symptom
fourth
studi
report
outcom
infect
passeng
diamond
princess
cruis
ship
hospitalis
japan
asymptomat
time
diagnosi
develop
symptom
median
followup
day
iqr
day
find
four
studi
dispar
pool
metaanalysi
figur
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
includ
two
transmiss
dynam
mathemat
model
studi
explicitli
address
question
tianjin
china
singapor
appli
statist
model
bayesian
framework
examin
gener
serial
interv
link
case
assumpt
incub
period
publish
studi
gener
period
shorter
incub
period
infector
indic
presymptomat
transmiss
found
proport
presymptomat
transmiss
ci
singapor
ci
tianjin
china
ferretti
et
al
develop
compartment
mathemat
model
inform
data
link
case
hubei
provinc
china
separ
transmiss
paramet
symptomat
asymptomat
presymptomat
environment
compon
baselin
scenario
assum
fraction
asymptomat
infect
cite
data
diamond
princess
reduc
infecti
asymptomat
case
found
base
case
scenario
presymptomat
patient
account
credibl
interv
total
transmiss
asymptomat
transmiss
total
provid
shini
app
ref
link
differ
assumpt
examin
rapid
systemat
review
found
upper
bound
ci
proport
asymptomat
infect
statist
model
studi
estim
cri
remain
asymptomat
empir
studi
estim
proport
peopl
presymptomat
go
develop
symptom
heterogen
combin
model
studi
infect
result
transmiss
presymptomat
individu
smaller
contribut
asymptomat
individu
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
strength
review
clearli
distinguish
infect
remain
asymptomat
throughout
cours
becom
symptomat
separ
proport
peopl
infect
contribut
overal
transmiss
popul
rapid
systemat
review
follow
publish
protocol
use
method
minimis
bia
whilst
increas
speed
review
process
live
systemat
review
updat
regularli
use
live
evid
databas
includ
preprint
one
main
limit
review
databas
includ
sourc
four
databas
cover
major
public
believ
miss
studi
would
chang
conclus
identifi
one
onlin
summari
asymptomat
infect
list
articl
found
search
five
electron
databas
publish
protocol
author
distinguish
asymptomat
presymptomat
infect
present
crosssect
studi
alongsid
longitudin
studi
mathemat
model
studi
review
gave
wide
rang
infect
might
asymptomat
advantag
review
systemat
review
although
includ
fewer
studi
report
find
empir
studi
follow
particip
least
day
last
exposur
quantifi
proport
asymptomat
infect
metaanalysi
find
systemat
review
support
claim
larg
major
infect
asymptomat
estim
ci
upper
bound
infect
remain
asymptomat
throughout
believ
analysi
like
overestim
true
proport
includ
contact
investig
includ
least
one
asymptomat
individu
stage
pandem
new
infecti
diseas
like
public
bia
rapid
public
case
report
newsworthi
find
personto
person
transmiss
asymptomat
individu
denomin
contact
investig
known
studi
liao
et
al
also
includ
cluster
asymptomat
case
larg
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
number
case
report
novel
manifest
diseas
also
featur
zika
epidem
analysi
publish
studi
show
estim
durat
infect
decreas
time
less
bias
studi
publish
anticip
larger
repres
studi
conduct
publish
proport
estim
asymptomat
decreas
statist
model
studi
mizumoto
account
right
censor
provid
upper
uncertainti
interv
asymptomat
infect
might
closer
true
proport
assum
incub
period
distribut
accur
level
durat
transmiss
individu
asymptomat
infect
known
review
three
asymptomat
case
report
sourc
subsequ
infect
within
famili
proport
peopl
presymptomat
could
determin
certainti
presum
distribut
date
detect
differ
studi
nevertheless
transmiss
presymptomat
individu
found
occur
one
three
day
symptom
onset
mathemat
model
studi
determin
overal
contribut
transmiss
individu
asymptomat
presymptomat
infect
popul
level
nonlinear
dynam
infect
transmiss
studi
includ
review
three
estim
two
studi
found
infect
result
transmiss
whilst
presymptomat
smaller
contribut
asymptomat
infect
consist
find
reassur
studi
use
differ
method
note
ganyani
et
al
use
data
serial
interv
deriv
estim
use
assumpt
proport
asymptomat
infect
find
differ
model
studi
interpret
show
transmiss
asymptomat
li
colleagu
found
infect
defin
undocu
appear
proport
composit
asymptomat
infect
infect
symptomat
diagnos
unreport
infect
mild
undiagnos
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
systemat
review
give
import
inform
inform
futur
research
public
health
decisionmak
intermedi
contribut
presymptomat
asymptomat
infect
overal
transmiss
mean
combin
prevent
enhanc
hand
respiratori
hygien
test
trace
isol
strategi
social
distanc
continu
need
social
distanc
measur
need
sustain
level
droplet
transmiss
close
contact
peopl
asymptomat
presymptomat
infect
occur
eas
restrict
howev
possibl
wide
access
test
contact
trace
rapid
isol
infect
individu
quarantin
close
contact
also
essenti
prevent
onward
transmiss
asymptomat
presymptomat
period
becom
infect
digit
proxim
track
need
supplement
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
includ
question
figur
flow
chart
identifi
exclud
includ
record
march
includ
metaanalysi
question
includ
metaanalysi
question
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
figur
risk
bia
studi
asymptomat
presymptomat
infect
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
protocol
registr
indic
review
protocol
exist
access
eg
web
address
avail
provid
registr
inform
includ
registr
number
elig
criteria
specifi
studi
characterist
eg
pico
length
followup
report
characterist
eg
year
consid
languag
public
statu
use
criteria
elig
give
rational
inform
sourc
describ
inform
sourc
eg
databas
date
coverag
contact
studi
author
identifi
addit
studi
search
date
last
search
search
present
full
electron
search
strategi
least
one
databas
includ
limit
use
could
repeat
studi
select
state
process
select
studi
ie
screen
elig
includ
systemat
review
applic
includ
metaanalysi
data
collect
process
describ
method
data
extract
report
eg
pilot
form
independ
duplic
process
obtain
confirm
data
investig
data
item
list
defin
variabl
data
sought
eg
pico
fund
sourc
assumpt
simplif
made
risk
bia
individu
studi
describ
method
use
assess
risk
bia
individu
studi
includ
specif
whether
done
studi
outcom
level
inform
use
data
synthesi
summari
measur
state
princip
summari
measur
eg
risk
ratio
differ
mean
